Seed Grant--Thoracic Radiology
The Society of Thoracic Radiology is offering seed grant support for young investigators to pursue novel research in thoracic imaging and related fields. Eligibility The principal investigator, or faculty mentor, should be a member of the STR. Preference will be given to Residents, Fellows, and Junior Faculty (within 5 years of completion of fellowship.) Awards Funding is $8,000 - $20,000 for a duration of one (1) year. Funds for computers and development of teaching models will not be considered. The grants will not pay for travel, overhead or indirect costs. Up to 50% of the seed grant amount could be used for salary support. Application Deadline February 15 July 31
Society of Thoracic Radiology c/o Matrix Meetings, Inc. P.O. Box 7169 Rochester, MN 55903-1026 507-288-5620 Fax: 507-288-0014 e-mail: str@thoracicrad.org
The 2009 Julie Martin Mid-Career Award in Aging Research Sponsored by The Ellison Medical Foundation Julie Martin (1929-2005) was trained in medical technology and art history at the University of Washington. Over a period of more than forty years, hundreds of visiting gerontologists from around the world were guests at her lovely Seattle home. She traveled widely with her husband, George M. Martin, Scientific Director of AFAR, helping him with field research in India, Syria, Turkey, Europe and Japan, work that eventually led to the identification of the helicase/exonuclease mutations responsible for the Werner syndrome, a striking segmental progeroid syndrome. Julie was devoted to family, friends and colleagues, and to her collection of folk art, which included some of her own creations. The Program The Ellison Medical Foundation and AFAR developed this program for outstanding mid-career scientists who propose novel directions of high importance to biological gerontology. Proposals in areas where NIH awards or other traditional sources are unlikely because the research is high risk, are particularly encouraged if they have the potential for leading to major new advances in our understanding of basic mechanisms of aging. Projects investigating age-related diseases are also supported, but only if approached from the point of view of how basic aging processes may lead to these outcomes. Projects concerning mechanisms underlying common geriatric functional disorders are also encouraged, as long as these include connections to fundamental problems in the biology of aging. Projects that deal strictly with clinical problems such as the diagnosis and treatment of disease, health outcomes, or the social context of aging are not eligible. Recipients of this award are expected to attend the AFAR Grantee Conference. The purpose of the meeting is to promote scientific and personal exchanges among recent AFAR grantees and experts in aging research. Eligibility Criteria The applicant must be an Associate Professor who achieved tenured status after December 1, 2005. Non-tenured Associate Professors at institutions with tenure (even if tenure is only offered at the Full Professor level) are not eligible. Applicants at institutions that do not offer tenure must demonstrate that their appointment is equivalent to that of an Associate Professor who received tenure status after December 1, 2005. The proposed research must be conducted at any type of not-for-profit setting in the United States. Applicants who are employees in the NIH Intramural program are not eligible. The following criteria are used to determine the merit of an application: Qualifications of the applicant Quality and promise of the proposed research Excellence of the research environment Questions about eligibility or suitability of the research project can be addressed to ">grants@afar.org Application Procedures
The deadline of receipt of applications and all supporting materials is December 16, 2008 at 5:00 p.m. EST. Please refer to the Julie Martin Mid-Career Award instruction sheet and application for complete application procedures. Incomplete applications cannot be considered. All candidates must submit applications endorsed by their institution. Applications are reviewed through a two-tier review system. The initial screening takes place in mid-April, after which candidates are advised of the status of their applications. A final decision about grant awards is made in early June. AFAR can provide critiques only for those applications that are reviewed at the second stage by their Review Committee. Funding will begin July 1, 2009. Two four-year awards of $500,000 will be made in 2009, at the level of $125,000 per year. In addition, up to 10% ($50,000) may be requested for administrative/indirect costs.
American Federation for Aging Research (AFAR) | 55 West 39th Street, 16th Floor | New York, NY 10018 Phone: (212) 703-9977 | Toll-free: (888) 582-2327 | Fax: (212) 997-0330 E-mail: grants@afar.org or info@afar.org
Therapeutics Development Initiative 2009 Pre-Proposal Receipt Date: January 20, 2009 – 6:00pm US ETThe Michael J. Fox Foundation for Parkinson’s Research (MJFF) announces the launch of its Therapeutics Development Initiative (TDI) for Spring 2009, a funding mechanism to support and stimulate preclinical Parkinson’s disease research at for-profit institutions. This funding program seeks to support preclinical development of Parkinson’s disease therapies which have the potential for fundamentally altering disease course and/or improving treatment of symptoms above and beyond current standards of care. Proposals must focus on key and critical preclinical studies necessary for developing, optimizing and evaluating therapeutic strategies that if successful can move into human testing. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the principal investigator who must be an employee of a for-profit entity. Academic investigators may have an advisory role in the project, but the operational and strategic ownership of the project must reside within the company. Investigators may seek up to two years of funding for preclinical development and testing of novel therapeutic approaches for the treatment or prevention of Parkinson’s disease. Please note that pre-proposals are mandatory and will be used to evaluate your proposal’s fit with the stated aims and review criteria of the RFP. All pre-proposals received in response to this program will be subjected to a triage process and only those pre-proposals deemed to be of suitable scientific merit will be invited to submit a full application. MJFF employs an expedited, abbreviated granting mechanism to accelerate discoveries and ultimately translate findings to PD patients more quickly. Conference Call MJFF will hold a 45 minute long conference call on December 16, 2008 at 12:00 PM U.S. Eastern Time to clarify and explain the Therapeutics Development Initiative 2009 program and to answer applicants' questions. To participate in this call, you must RSVP via email to conferencecalls@michaeljfox.org. Participants will receive a reply with call-in details.
While there are no restrictions as to the specific approaches to be studied under this RFP, successful applications are most likely to focus on at least one of the following categories: o Neuroprotective strategies focused on slowing or preventing the process of neuronal death. o Neuroregenerative strategies to restore or replace neuronal function. o Novel drug delivery mechanisms and/or surgical procedures. o Innovative therapeutic approaches to treat the motor and non-motor symptoms of PD, including cognitive dysfunction, autonomic dysfunction, sleep disorders, or depression among others. o Therapeutic approaches to alleviate complications of PD treatment including dyskinesias, etc.
If you would like to contact the Foundation, please call toll-free at 1-800-708-7644, or contact us by regular mail at the following address: The Michael J. Fox Foundation for Parkinson's Research Church Street Station P.O. Box 780 New York, NY 10008-0780
Grants Prorgam
Grant Deadline is January 15, 2009
The Arthritis National Research Foundation (ANRF) is dedicated to funding highly qualified investigators associated with major research institutes, universities and hospitals throughout the country who are seeking to discover new knowledge for the prevention, treatment and cure of arthritis and other rheumatic diseases. ANRF's Board of Directors and Scientific Advisory Board are committed to providing uninterrupted research in the search for new therapies and a cure. The results will mean improved treatment for the 66 million Americans who suffer from some form of arthritis. The Scientific Advisory Board and the Board of Directors review grant proposals annually. Clinical and basic studies will be considered. Clinical studies should have a translational component that helps reveal the underlying mechanisms or response to therapy. Priority will be given to investigators possessing either a M.D. and/or Ph.D. degree or equivalent, affiliated with a qualified, non-profit institution. Preference will be given to senior post-doctoral investigators transitioning to independent investigator status and new assistant professors. Applicant may not have (or ever had) an NIH R01 grant or equivalent. Grants are awarded for one year. First-year recipients may submit a detailed progress report by mid-January during the year of their award, requesting a second year. See guidelines for details. NEW FUNDING LEVEL Grants awarded will be in the range of $20,000 to $75,000. Partial funding may be awarded if grantee has documentation that the remainder of the funding for proposed research has been acquired.
The Foundation will fund salaries, supplies and equipment directly related to the proposed studies. Overhead or indirect costs will not be funded. The Foundation will seek to fund at least one grant each year focusing on juvenile arthritis. ANRF routinely funds 8-15 grants per year. Applications not in strict compliance with stated policies and guidelines will be subject to administrative inactivation. Additional administrative review may be rendered to determine priority for funding when multiple proposals are received from a single laboratory, Division or Department. No-Cost Time Extensions on ANRF Grant Awards No-cost extensions may be approved for ANRF grant awards, not to exceed three months. Requests from current grant recipients must be submitted in writing (e-mail acceptable). Transfer of ANRF Grant Awards If an investigator changes institutions during the grant award period, the ANRF requests the following: 1) A letter from the new institution, preferably the head of the department, stating that the investigator will be working on the same project and have the laboratory facilities and time available to do so. The letter should indicate the start date of the investigator in the new environment, as well as the contact information, address, e-mail, phone for disbursement of the remaining ANRF grant funds. The letter must be co-signed by the responsible business/grants management official of the new institution. 2) The original institution is responsible for sending any unused funds, prorated depending on the date, to the ANRF. We will then forward a new check for the unused funds to the new institution.
Arthritis National Research Foundation 200 Oceangate, Suite 830 Long Beach, CA 90802 Tel: 1-800-588-2873 Fax: 562-983-1410 anrf@ix.netcom.com
IADR/GlaxoSmithKline Innovation in Oral Care Awards Supported by GlaxoSmithKline Deadline: December 1, 2008 INTRODUCTION: The Innovation in Oral Care Awards (“Award(s)”) are jointly sponsored by IADR and GlaxoSmithKline (GSK), with funding provided exclusively by GSK. The IADR mission is to advance research and increase knowledge for the improvement of oral health worldwide. It does so through its Divisions and Sections as well as in partnership with international dental associations, industry, health agencies, and scientific and educational professional organizations. These innovation awards offer opportunities for investigators to conduct dental research that will have a direct impact on the oral health of the public. As a leader in consumer oral care, GSK recognizes the need for pioneers to produce innovative technologies that can be used routinely by the public to maintain and improve oral health and quality of life. The Award(s) is intended to help investigators pursue innovative and novel research in oral care, above and beyond the bounds of traditional dental research. Competitive Award(s), of up to $75,000 each, will be provided to recipients to advance oral care programs directed toward the development of innovative and novel compounds, biomaterials or devices that can be used ultimately at the public health level. Examples of areas of interest could include, but not be limited to: inhibition or removal of biofilms etc. adhering to natural or artificial surfaces, modification of those surfaces to inhibit biofilms and other deposits, stains and odors, adhesives for removable prosthetic devices, inhibition of tooth surface loss and gingival recession, and amelioration of their effects, and counteracting the oral effects of dry mouth, systemic illness, hormonal disturbances or physiological aging. The Award(s) will be provided in the form of an unrestricted research grant which carries no obligation to the recipient’s organization for licensure, patenting, or transfer confidential information, although GSK may discuss the possibility of future collaboration with some applicants. CRITERIA FOR PROPOSALS: 1) For the purposes of this Award Program, oral care is defined as: a) products, devices or delivery systems used frequently by consumers to maintain or improve their oral health status and quality of life, and /or b) devices fabricated by the assistance of dental professionals and placed in the oral cavity, and which require frequent or daily maintenance by the consumer. 2) Any proposed innovation or new technology should provide significant benefits to the consumer, such as improved oral health and/or quality of life. 3) Ultimately the proposed innovations or technologies should be available to large numbers of people through retail channels such as ‘over-the-counter’ (OTC) or general sale. Initially, however, it may be appropriate for availability to be on a prescription basis for a limited period before transitioning to OTC. 4) Restorative materials, dental instruments and equipment, and diagnostics for non-oral conditions should not receive much consideration unless the technological advance provides significant benefit to the oral health and quality of life status of the public. ELIGIBILITY: The principal investigator listed in the application must be a current member of, or at the time of submission have made bona fide application to, IADR. To fulfill the quest for innovation, proposals should be collaboratively sponsored by at least one researcher whose principal expertise is in an area of biotechnology other than a dental science. The intent is to encourage collaboration with researchers from outside the dental institution; nevertheless, the most important criterion involves the innovative nature of the proposed research. In any case, applicants should possess advanced degrees and must hold an affiliation with an academic center, not-for-profit institution, or for-profit entities such as biotechnology start-up companies. Letters of support from the principal investigator’s (PI) institution are required and should describe the nature of the PI’s appointment and commitments to the PI, such as lab and office space, technical assistance or travel funds.
APPLICATIONS and FURTHER INFORMATION: Except for disclosures to IADR or GSK as agreed to by applicant, all applicants shall agree not to disclose their application or the contents thereof to others until June 30, 2009. After the judging process has been completed, GSK will have access to applicant names, their institutions, the proposal title and abstract only, and may wish to discuss potential commercialization of the concepts disclosed in the applications with the applicants, if the applicants so agree. Completed applications should be submitted online (www.dentalresearch.org) before the closing date of December 1, 2008. Further information can be obtained from the Sheri S. Herren, Awards, Fellowships & Grants Manager (Email: sherren@iadr.org). Interested parties are welcome to submit a brief proposal letter outlining the research to IADR and asking for a determination as to whether such research would qualify for consideration.
The Albany Medical Center Prize serves to encourage and recognize extraordinary and sustained contributions to improving health care and promoting innovative biomedical research. Awarded annually, the $500,000 prize is the largest prize in medicine in the United States and is bestowed to any physician or scientist, or group, whose work has led to significant advances in the fields of health care and scientific research with demonstrated translational benefits applied to improved patient care. The prize is a legacy to its founder - the late Morris "Marty" Silverman. At the inaugural awards ceremony in Albany, NY in March 2001, Albany Medical Center Prize founder Marty Silverman started a tradition that will be carried on for the duration of the Prize - 100 years. Marty's promise was to light one candle each year to honor that year's recipient.
Prize Criteria The Albany Medical Center Prize has been created to provide national and international recognition to a physician, biomedical scientist, or group of physicians or scientists, who have made extraordinary and sustained leadership contributions to improving healthcare and patient care; or who have successfully pursued innovative biomedical research with demonstrated translational benefits applied to improved patient care. Each year's Albany Medical Center Prize winner will have demonstrated significant outcomes that offer medical value of national or international importance. Albany Medical Center Prize winner activities will include but not be limited to disease and injury management, clinical research, and basic science investigations of diseases and injuries, leading to new discoveries and improved clinical outcomes. Those honored will be practitioners and/or scientists whose accomplishments and outcomes have been demonstrated in the past quarter century, with preference to demonstrated accomplishments in the past decade. The recipient has full discretionary use of the Albany medical Center Prize, although it is the Albany Medical Center Prize Committee's hope that at least a portion of the award will be used to advance further positive outcomes in his or her field of expertise. The Albany Medical Center Prize is designed to be both a public award and an important resource for sustaining excellence. Nominations for the 2009 Albany Medical Center Prize in Medicine and Biomedical Research will be accepted through January 9, 2009. A letter of nomination must include a description of the nominee's extraordinary or sustained contribution to improving health care and patient care; or a description of innovative biomedical research with demonstrated translational benefits applied to improved patient care. The Selection Committee also requests two additional letters of support for each nomination, as well as the curriculum vitae of each person nominated, with a bibliography of important publications and articles. No self nominations will be accepted. Nominations by interested parties may be directed to: Teri A. Cerveny, Secretary Senior Vice President, Development The Albany Medical Center Prize in Medicine and Biomedical Research c/o Albany Medical Center, Center Building, 628 Madison Avenue - 1st Floor Albany, New York 12208 Phone: 518-262-8043 Fax: 518-262-4769 Email: AMCprize@mail.amc.edu
123next
